NCT06523595View on ClinicalTrials.gov

Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Pain
Interventions
DRUG

VX-993

Suspension for Oral Administration.

DRUG

Metformin

Tablets for Oral Administration.

Trial Locations (1)

84124

ICON Salt Lake City, Salt Lake City

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06523595 - Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults | Biotech Hunter | Biotech Hunter